Literature DB >> 19295332

Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease.

Vilija R Joyce1, Paul G Barnett, Ahmed M Bayoumi, Susan C Griffin, Tassos C Kyriakides, Wei Yu, Vandana Sundaram, Mark Holodniy, Sheldon T Brown, William Cameron, Mike Youle, Mark Sculpher, Aslam H Anis, Douglas K Owens.   

Abstract

OBJECTIVE: To assess and compare alternative approaches of measuring preference-based health-related quality of life (HRQoL) in treatment-experienced HIV patients and evaluate their association with health status and clinical variables.
DESIGN: Cross-sectional study.
SETTING: Twenty-eight Veterans Affairs hospitals in the United States, 13 hospitals in Canada, and 8 hospitals in the United Kingdom. PATIENTS: Three hundred sixty-eight treatment-experienced HIV-infected patients enrolled in the Options in Management with Antiretrovirals randomized trial. MEASUREMENTS: Baseline sociodemographic and clinical indicators and baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HIV), the EQ-5D, the EQ-5D visual analog scale (EQ-5D VAS), the Health Utilities Index Mark 3 (HUI3), and standard gamble (SG) and time trade-off (TTO) techniques.
RESULTS: The mean (SD) baseline HRQoL scores were as follows: MOS-HIV physical health summary score 41.70 (11.16), MOS-HIV mental health summary score 44.76 (11.38), EQ-5D 0.77 (0.19), HUI3 0.59 (0.32), EQ-5D VAS 65.94 (21.71), SG 0.75 (0.29), and TTO 0.80 (0.31). Correlations between MOS-HIV summary scores and EQ-5D, EQ-5D VAS, and HUI3 ranged from 0.60 to 0.70; the correlation between EQ-5D and HUI3 was 0.73; and the correlation between SG and TTO was 0.43. Preference-based HRQoL scores were related to physical, mental, social, and overall health as measured by MOS-HIV. Concomitant medication use, CD4 cell count, and HIV viral load were related to some instruments' scores.
CONCLUSIONS: On average, preference-based HRQoL for treatment-experienced HIV patients was decreased relative to national norms but also highly variable. Health status and clinical variables were related to HRQoL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19295332     DOI: 10.1097/QAI.0b013e31818ce6f3

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

1.  Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV disease.

Authors:  Ahmed M Bayoumi; Paul G Barnett; Vilija R Joyce; Susan C Griffin; Huiying Sun; Nick J Bansback; Mark Holodniy; Gillian Sanders; Sheldon T Brown; Tassos C Kyriakides; Brian Angus; D William Cameron; Aslam H Anis; Mark Sculpher; Douglas K Owens
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-01       Impact factor: 3.731

2.  The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States.

Authors:  Elisa F Long; Margaret L Brandeau; Douglas K Owens
Journal:  Ann Intern Med       Date:  2010-12-21       Impact factor: 25.391

Review 3.  Health-related quality of life assessment after antiretroviral therapy: a review of the literature.

Authors:  Harleen Gakhar; Amanda Kamali; Mark Holodniy
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

4.  Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.

Authors:  Mark Holodniy; Sheldon T Brown; D William Cameron; Tassos C Kyriakides; Brian Angus; Abdel Babiker; Joel Singer; Douglas K Owens; Aslam Anis; Ruth Goodall; Fleur Hudson; Mirek Piaseczny; John Russo; Martin Schechter; Lawrence Deyton; Janet Darbyshire
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

Review 5.  Longitudinal and cross sectional assessments of health utility in adults with HIV/AIDS: a systematic review and meta-analysis.

Authors:  Bach Xuan Tran; Long Hoang Nguyen; Arto Ohinmaa; Rachel Marie Maher; Vuong Minh Nong; Carl A Latkin
Journal:  BMC Health Serv Res       Date:  2015-01-22       Impact factor: 2.655

6.  The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States.

Authors:  Blythe J S Adamson; Josh J Carlson; James G Kublin; Louis P Garrison
Journal:  Vaccines (Basel)       Date:  2017-05-24

7.  Interrelationships among common symptoms in the elderly and their effects on health-related quality of life: a cross-sectional study in rural Korea.

Authors:  Sujeong Mun; Kihyun Park; Younghwa Baek; Siwoo Lee; Jong-Hyang Yoo
Journal:  Health Qual Life Outcomes       Date:  2016-10-13       Impact factor: 3.186

8.  Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis.

Authors:  Emanuel Krebs; Benjamin Enns; Linwei Wang; Xiao Zang; Dimitra Panagiotoglou; Carlos Del Rio; Julia Dombrowski; Daniel J Feaster; Matthew Golden; Reuben Granich; Brandon Marshall; Shruti H Mehta; Lisa Metsch; Bruce R Schackman; Steffanie A Strathdee; Bohdan Nosyk
Journal:  PLoS One       Date:  2019-05-30       Impact factor: 3.240

9.  The time horizon matters: results of an exploratory study varying the timeframe in time trade-off and standard gamble utility elicitation.

Authors:  Louis S Matza; Kristina S Boye; David H Feeny; Lee Bowman; Joseph A Johnston; Katie D Stewart; Kelly McDaniel; Jessica Jordan
Journal:  Eur J Health Econ       Date:  2015-11-26

10.  Health-related quality of life and associated factors in people with HIV: an Irish cohort study.

Authors:  Sherly George; Colm Bergin; Susan Clarke; Grainne Courtney; Mary B Codd
Journal:  Health Qual Life Outcomes       Date:  2016-08-05       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.